RTW INVESTMENTS, LP — 13F Holdings & Portfolio

CIK 1493215 · latest 13F-HR filed 2026-08-14

RTW INVESTMENTS, LP manages $11.71B in 13F-reported U.S. long-equity assets across 84 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MDGL (9.14%), ARGX (5.62%), PTCT (5.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 9 new positions and exited 13; 48 existing positions rose in reported value and 15 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$11.71B

Long-equity book

Holdings
84

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+9 / −13 / ↑48 / ↓15

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 47.7%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 30, 2026.

Assets Under Management
$14.14B
Discretionary
$14.14B
Employees
70
Accounts
10
Address
40 10TH AVENUE
7TH FLOOR
NEW YORK, NY 10014
Phone
(646) 597-6980
This firm reports 4 disclosure items on its registration.
Name Title / Status Ownership Type
AURIGEMA, ROBERT, JOHN ControlPARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
since Aug 2020
Less than 5%Individual
FONG, PETER, M ControlPARTNER, PRESIDENT
since Jan 2022
Less than 5%Individual
KENNEDY-SMITH, JOSH ControlPARTNER, RESEARCH ANALYST
since Jan 2024
Less than 5%Individual
MAKKER, GOTAM ControlPARTNER, HEAD OF STRATEGIC INVESTMENTS
since Sep 2023
Less than 5%Individual
NGUYEN, TONY ControlPARTNER, RESEARCH ANALYST
since Jan 2025
Less than 5%Individual
PATEL, DARSHAN, VISHNU ControlCHIEF COMPLIANCE OFFICER, GENERAL COUNSEL
since Feb 2021
Less than 5%Individual
RTW INVESTMENTS GP, LLC ControlGENERAL PARTNER OF RTW INVESTMENTS, LP
since Apr 2016
Less than 5%Domestic Entity
SEITER, CHRISTOPHER, JOHN ControlCHIEF CORPORATE FINANCE OFFICER
since Apr 2021
Less than 5%Individual
SIROTA, STEPHANIE, ANNE ControlPARTNER, CHIEF BUSINESS OFFICER
since Jan 2014
Less than 5%Individual
WONG, RODERICK, TZE IAN ControlMANAGING PARTNER, CHIEF INVESTMENT OFFICER
since Sep 2009
50–75%Individual
YALAMANCHI, NAVEEN ControlPARTNER, PORTFOLIO MANAGER
since Jan 2016
5–10%Individual
Ownership & leadership changes · 13 filings with changes since Oct 31, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 30, 2026 filing
  • No longer listedLOUGHRAN, SABERA, REZA · PARTNER EMERITUS · Less than 5% · control person · listed since Oct 2009
  • AddedNGUYEN, TONY · PARTNER, RESEARCH ANALYST · Less than 5% · control person
Mar 28, 2025 filing
  • AddedKENNEDY-SMITH, JOSH · PARTNER, RESEARCH ANALYST · Less than 5% · control person
  • ChangedPATEL, DARSHAN, VISHNU · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL
  • ChangedWONG, RODERICK, TZE IAN · ownership 75% or more → 50–75%
  • ChangedYALAMANCHI, NAVEEN · ownership 10–25% → 5–10%
Mar 28, 2024 filing
  • AddedMAKKER, GOTAM · PARTNER, HEAD OF STRATEGIC INVESTMENTS · Less than 5% · control person
  • ChangedAURIGEMA, ROBERT, JOHN · title CHIEF FINANCIAL OFFICER → PARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
  • ChangedFONG, PETER, M · title PARTNER, CHIEF DEVELOPMENT OFFICER → PARTNER, PRESIDENT
  • ChangedLOUGHRAN, SABERA, REZA · title PARTNER, CHIEF ADMINISTRATIVE OFFICER → PARTNER EMERITUS
Mar 30, 2023 filing
  • ChangedLOUGHRAN, SABERA, REZA · title CHIEF ADMINISTRATIVE OFFICER → PARTNER, CHIEF ADMINISTRATIVE OFFICER
  • ChangedSIROTA, STEPHANIE, ANNE · title CHIEF BUSINESS OFFICER → PARTNER, CHIEF BUSINESS OFFICER
  • ChangedYALAMANCHI, NAVEEN · ownership 5–10% → 10–25%
Mar 30, 2022 filing
  • No longer listedLEE, ALICE · SENIOR COUNSEL · Less than 5% · listed since Feb 2019
  • AddedFONG, PETER, M · PARTNER, CHIEF DEVELOPMENT OFFICER · Less than 5% · control person
  • AddedSEITER, CHRISTOPHER, JOHN · CHIEF CORPORATE FINANCE OFFICER · Less than 5% · control person
  • ChangedAURIGEMA, ROBERT, JOHN · now a control person
  • ChangedLOUGHRAN, SABERA, REZA · title CHIEF OPERATING OFFICER → CHIEF ADMINISTRATIVE OFFICER
  • ChangedPATEL, DARSHAN, VISHNU · now a control person
  • ChangedSIROTA, STEPHANIE, ANNE · now a control person
  • ChangedWONG, RODERICK, TZE IAN · title MANAGING PARTNER → MANAGING PARTNER, CHIEF INVESTMENT OFFICER
  • ChangedYALAMANCHI, NAVEEN · title LIMITED PARTNER → PARTNER, PORTFOLIO MANAGER; now a control person
Mar 30, 2021 filing
  • AddedSIROTA, STEPHANIE, ANNE · CHIEF BUSINESS OFFICER · Less than 5%
  • ChangedLOUGHRAN, SABERA, REZA · ownership 5–10% → Less than 5%
Feb 19, 2021 filing
  • AddedAURIGEMA, ROBERT, JOHN · CHIEF FINANCIAL OFFICER · Less than 5%
  • AddedPATEL, DARSHAN, VISHNU · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ChangedLEE, ALICE · title CHIEF COMPLIANCE OFFICER → SENIOR COUNSEL
  • ChangedLOUGHRAN, SABERA, REZA · title CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER → CHIEF OPERATING OFFICER
Mar 5, 2019 filing
  • AddedLEE, ALICE · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ChangedLOUGHRAN, SABERA, REZA · title CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER
Mar 29, 2018 filing
  • ChangedLOUGHRAN, SABERA, REZA · ownership Less than 5% → 5–10%
  • ChangedYALAMANCHI, NAVEEN · title PORTFOLIO MANAGER → LIMITED PARTNER; no longer a control person
Mar 29, 2017 filing
  • AddedRTW INVESTMENTS GP, LLC · GENERAL PARTNER OF RTW INVESTMENTS, LP · Less than 5% · control person
  • ChangedWONG, RODERICK, TZE IAN · title MANAGING MEMBER → MANAGING PARTNER
Older changes (4 more filings)
Mar 30, 2016 filing
  • AddedYALAMANCHI, NAVEEN · PORTFOLIO MANAGER · 5–10% · control person
Aug 5, 2014 filing
  • ChangedLOUGHRAN, SABERA, REZA · title DIRECTOR OF FINANCE & OPERATIONS/CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER/CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER
Jun 4, 2013 filing
  • ChangedLOUGHRAN, SABERA, REZA · title DIRECTOR OF FINANCE & OPERATIONS → DIRECTOR OF FINANCE & OPERATIONS/CHIEF COMPLIANCE OFFICER
Oct 31, 2012 filing (earliest on record)
  • ListedLOUGHRAN, SABERA, REZA · DIRECTOR OF FINANCE & OPERATIONS · Less than 5% · control person
  • ListedWONG, RODERICK, TZE IAN · MANAGING MEMBER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

RTW INVESTMENTS, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 MADRIGAL PHARMACEUTICALS INC MDGL 558868105 $1.07B 9.14% 1,993,687 SH
2 ARGENX SE ARGX 04016X101 $658.2M 5.62% 709,446 SH
3 PTC THERAPEUTICS INC PTCT 69366J200 $631.9M 5.39% 7,746,415 SH
4 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $620.4M 5.30% 5,061,175 SH
5 CG ONCOLOGY INC CGON 156944100 $605.0M 5.16% 8,514,590 SH
6 INSMED INC INSM 457669307 $516.3M 4.41% 4,842,880 SH
7 TANGO THERAPEUTICS INC TNGX 87583X109 $434.5M 3.71% 13,900,620 SH
8 SPYRE THERAPEUTICS INC SYRE 00773J202 $377.5M 3.22% 4,251,996 SH
9 CELCUITY INC CELC 15102K100 $345.8M 2.95% 3,304,903 SH
10 ERASCA INC ERAS 29479A108 $328.8M 2.81% 17,946,754 SH
11 RADNET INC RDNT 750491102 $298.9M 2.55% 4,846,958 SH
12 ORUKA THERAPEUTICS INC ORKA 687604108 $298.7M 2.55% 3,139,030 SH
13 NATERA INC NTRA 632307104 $271.4M 2.32% 1,000,000 SH
14 ULTRAGENYX PHARMACEUTICAL IN RARE 90400D108 $260.3M 2.22% 7,796,895 SH
15 IRHYTHM HOLDINGS INC IRTC 450056106 $259.6M 2.22% 2,182,631 SH
16 CYTOKINETICS INC CYTK 23282W605 $243.8M 2.08% 2,862,003 SH
17 KAILERA THERAPEUTICS INC KLRA 482931102 $237.4M 2.03% 10,776,820 SH
18 ESTABLISHMENT LABS HLDGS INC ESTA G31249108 $227.9M 1.95% 2,655,695 SH
19 GUARDANT HEALTH INC GH 40131M109 $222.2M 1.90% 1,481,033 SH
20 NEUROCRINE BIOSCIENCES INC NBIX 64125C109 $213.7M 1.82% 1,267,925 SH
21 TARSUS PHARMACEUTICALS INC TARS 87650L103 $211.3M 1.80% 3,357,059 SH
22 STOKE THERAPEUTICS INC STOK 86150R107 $184.0M 1.57% 5,623,525 SH
23 UNIQURE NV QURE N90064101 $181.5M 1.55% 3,941,572 SH
24 ACADIA PHARMACEUTICALS INC ACAD 004225108 $180.8M 1.54% 7,144,524 SH
25 REPLIGEN CORP RGEN 759916109 $169.3M 1.45% 1,240,637 SH
26 UROGEN PHARMA LTD URGN M96088105 $167.2M 1.43% 4,543,895 SH
27 GH RESEARCH PLC GHRS G3855L106 $159.5M 1.36% 5,933,815 SH
28 IMMUNOCORE HLDGS PLC IMCR 45258D105 $154.6M 1.32% 4,869,798 SH
29 COMPASS PATHWAYS PLC CMPS 20451W101 $151.4M 1.29% 10,700,974 SH
30 IMMATICS N.V IMTX N44445109 $131.1M 1.12% 12,946,176 SH
31 ZAI LAB LTD ZLAB 98887Q104 $124.9M 1.07% 6,574,032 SH
32 IMMUNOVANT INC IMVT 45258J102 $122.4M 1.05% 3,177,849 SH
33 BELITE BIO INC BLTE 07782B104 $110.2M 0.94% 715,332 SH
34 XENCOR INC XNCR 98401F105 $109.1M 0.93% 6,777,461 SH
35 TAYSHA GENE THERAPIES INC TSHA 877619106 $92.3M 0.79% 13,560,258 SH
36 COGENT BIOSCIENCES INC COGT 19240Q201 $89.4M 0.76% 2,309,021 SH
37 ALKERMES PLC ALKS G01767105 $87.6M 0.75% 1,672,356 SH
38 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $86.3M 0.74% 1,607,507 SH
39 REPLIMUNE GROUP INC REPL 76029N106 $82.0M 0.70% 7,411,581 SH
40 CASTLE BIOSCIENCES INC CSTL 14843C105 $66.3M 0.57% 2,778,335 SH
41 CANDEL THERAPEUTICS INC CADL 137404109 $66.1M 0.56% 6,422,018 SH
42 ROCKET PHARMACEUTICALS INC RCKT 77313F106 $60.5M 0.52% 17,687,772 SH
43 KODIAK SCIENCES INC KOD 50015M109 $58.0M 0.49% 1,487,934 SH
44 AKTIS ONCOLOGY INC AKTS 01021M104 $51.3M 0.44% 1,592,043 SH
45 AXOGEN INC AXGN 05463X106 $46.7M 0.40% 1,011,576 SH
46 DANAHER CORP DEL DHR 235851102 $43.8M 0.37% 230,000 SH
47 CULLINAN THERAPEUTICS INC CGEM 230031106 $43.1M 0.37% 2,364,347 SH
48 NEUROGENE INC NGNE 64135M105 $42.8M 0.37% 1,362,456 SH
49 HINGE HEALTH INC HNGE 433313103 $41.5M 0.35% 500,000 SH
50 ORCHESTRA BIOMED HLDGS INC OBIO 68572M106 $41.2M 0.35% 9,556,063 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $11.71B 84 0001493215-26-000164
2026-03-31 2026-05-15 $10.05B 88 0001493215-26-000130
2025-12-31 2026-02-17 $9.98B 91 0001493215-26-000060
2025-09-30 2025-11-14 $8.12B 74 0001493215-25-000054
Filer Information
Address
40 10TH AVENUE
7TH FLOOR
NEW YORK, NY 10014
Phone
(646) 597-6980
Filing Manager
RTW INVESTMENTS, LP
NEW YORK, NY
Signatory
Roderick Wong
Managing Partner